Manipal Health Enterprises IPO opens on July 27, 2026, and closes on July 29. The issue combines a fresh issue of ₹8,000 crore and an offer for sale of up to 4.32 crore equity shares. SEBI approved the IPO on July 3, 2026. Price band, lot size, and total issue size in rupee terms are yet to be declared.
Introduction
Manipal Health runs one of India's largest private hospital networks, with 38 hospitals and over 10,700 licensed beds as of September 2025. The fresh issue proceeds are primarily going toward debt reduction at its subsidiary Manipal Hospitals Private Limited. This is a balance sheet clean-up as much as it is a listing event.
Manipal Health IPO: Key highlights
| Detail | Information |
| IPO open date | July 27, 2026 |
| IPO close date | July 29, 2026 |
| Issue type | Fresh issue + OFS |
| Fresh issue | ₹8,000 crore |
| OFS | Up to 4,32,27,668 equity shares |
| Face value | ₹2 per share |
| Price band | To be declared |
| Lot size | To be declared |
| Listing exchanges | BSE and NSE |
| Allotment date | July 30, 2026 |
| Listing date | August 1, 2026 |
| Registrar | KFin Technologies Ltd. |
| Lead managers | Kotak Mahindra Capital, Axis Capital, Goldman Sachs, Jefferies, JP Morgan, UBS, DBS Bank |
| QIB quota | Up to 50% |
| HNI quota | At least 15% |
| Retail quota | At least 35% |
Manipal Health IPO dates and timeline
SEBI gave its approval on July 3, 2026. The subscription opens July 27 and closes July 29. The allotment is scheduled for July 30, with a listing on August 1.
| Event | Date |
| SEBI approval | July 3, 2026 |
| IPO open | July 27, 2026 |
| IPO close | July 29, 2026 |
| Allotment finalisation | July 30, 2026 |
| Refund initiation | July 31, 2026 |
| Share credit to demat | July 31, 2026 |
| Listing on BSE and NSE | August 1, 2026 |
Manipal Health IPO price band, lot size & minimum investment
Price band and lot size have not been declared. Both will be in the Red Herring Prospectus before the subscription window opens. Applications go through UPI or ASBA. The quota split is up to 50% for QIBs, at least 35% for retail, and at least 15% for HNIs. Verify all details from the final RHP before applying.
Manipal Health IPO issue size and offer structure
Fresh issue
₹8,000 crore. Proceeds go into the business for specific purposes below.
Offer for sale (OFS)
Up to 4,32,27,668 equity shares of face value ₹2 each. Proceeds go to selling shareholders.
Total IPO size
Not finalised. Will be confirmed once the price band is declared.
Shareholding pattern before and after IPO
Pre-IPO promoter holding is 81.42%. Promoters include Ranjan Ramdas Pai, Manipal Global Health Services, MEMG International Ltd., Kangto Investments, Imperius Healthcare Investments, and Kabru Investments. Post-IPO shareholding will be updated after the final issue structure is confirmed.
Objectives of the IPO
₹5,378 crore goes toward repaying borrowings of Manipal Hospitals Private Limited. As of January 2026, consolidated outstanding borrowings stood at approximately ₹10,612 crore. Paying down over half of that materially improves the debt profile and cuts interest costs.
₹574 crore goes toward acquiring the remaining minority stake in Sahyadri Hospitals Private Limited, moving from partial to full ownership and consolidating Western India's presence. The balance goes toward general corporate purposes.
About Manipal Health Enterprises
Manipal Health Enterprises is part of the Manipal Group, founded by T.M.A. Pai. The company runs multi-specialty hospitals and clinics focused on tertiary and quaternary care.
Company overview
Headquartered in Bengaluru, the company operates hospitals, clinics, and diagnostic centres across India. It claims leadership in Bengaluru, Kolkata, and Pune, which is a geographic spread most private chains don't have.
India's second-largest hospital chain
By bed capacity on a pro forma basis, Manipal Health Enterprises is among the top two private hospital chains in India.
Hospital network and bed capacity
38 hospitals, 10,761 licensed beds as of September 2025. On a pro forma basis with recent acquisitions, that becomes 48 hospitals and 12,367 beds. Plus 17 clinics.
Specialties and healthcare services
Cardiac sciences, oncology, neurosciences, gastrosciences, orthopaedics, renal sciences, and organ transplants. These are high-complexity specialties where clinical reputation matters and pricing holds up better than general medicine.
Geographic presence
Bengaluru, Kolkata, Pune, Mangaluru, Goa, and other cities. Metro and non-metro presence reduces the concentration risk that pure metro chains carry.
Key acquisitions and growth strategy
Revenue more than doubled between FY23 and FY25, largely through acquisitions. The strategy is now shifting toward integrating what's been bought, paying down debt, and improving margins rather than continuing aggressive expansion.
Business model
Inpatient healthcare services
Surgeries, critical care, and complex procedures requiring hospitalisation. The highest-value revenue line, where speciality reputation directly affects pricing.
Outpatient services
Consultations and non-surgical treatments. Outpatient volumes support bed utilisation and feed referrals into inpatient procedures over time.
Diagnostics
In-house labs and imaging serving both hospital patients and external referrals. Improves clinical turnaround without needing additional beds.
Pharmacy
In-hospital pharmacies tied to patient volumes and occupancy. Recurring but margin-sensitive.
International patients
Medical tourism from African countries, the Middle East, and Southeast Asia. International patients typically generate higher revenue per case.
Digital healthcare
Telemedicine and patient engagement platforms that extend reach beyond physical locations.
Financial performance
| Metric | FY23 | FY24 | FY25 | H1 FY26 |
| Total income | ₹4,927.57 Cr | ₹6,265.17 Cr | ₹9,409.12 Cr | ₹5,436.31 Cr |
| PAT | ₹414.20 Cr | ₹533.20 Cr | ₹534.80 Cr | ₹319.47 Cr |
| EBITDA | ₹1,228.24 Cr | ₹1,596.98 Cr | ₹2,455.03 Cr | ₹1,439.15 Cr |
| EBITDA margin | -- | -- | 26.65% | 27.99% |
| PAT margin | -- | -- | 5.77% | 6.01% |
| ROCE | -- | -- | 26.98% | -- |
Revenue growth has been large but acquisition-driven. The EBITDA margin is improving and is now nearly 28% in H1 FY26. PAT in absolute terms is growing, but the PAT margin is thin at around 5 to 6%, reflecting the high depreciation and interest burden of running a debt-funded hospital network at this scale.
IPO valuation analysis
The price band is undeclared, so no precise P/E calculation is possible yet. FY25 PAT was ₹534.80 crore on a pro forma consolidated basis. Any valuation should be revisited once the band is out.
Listed hospital peers like Apollo Hospitals and Max Healthcare trade at significant premiums to earnings. Manipal Health's debt load and thin PAT margin are what will determine where investors price it relative to those peers. The debt repayment from fresh issue proceeds improves net profitability going forward, which is the key variable to watch when the price band comes out.
Strengths of Manipal Health
- Among India's largest private hospital networks by bed capacity, with metro leadership in three cities
- Specialty mix weighted toward cardiology, oncology, and neurosciences where pricing is stronger
- EBITDA margin improving steadily, reaching nearly 28% by H1 FY26
- International patient base adding higher revenue per case
- Debt reduction from IPO proceeds will improve net profitability once interest costs fall
- Seven lead managers, including Goldman Sachs, JP Morgan, and Jefferies signal serious global institutional outreach
Risks investors should know
- Even after ₹5,378 crore is repaid, meaningful debt remains on the balance sheet
- PAT margin of 5.77% in FY25 is thin. High depreciation and interest costs leave limited buffer
- Revenue growth between FY23 and FY25 was largely acquisition-driven. Proforma numbers need careful reading
- ₹574 crore going into Sahyadri increases concentration in Western India
- Pricing pressure from insurers and government health schemes can cap revenue per bed
Should you apply for the Manipal Health IPO?
The hospital network is real, and the scale is genuine. Improving EBITDA margins and a clear debt-reduction plan are positives going into the listing. The unknowns are the price band and the valuation multiple it implies relative to Apollo and Max Healthcare, which already trade at premium multiples.
For long-term investors who want private healthcare exposure, this is one of the more credible listings of 2026. For traders chasing listing gains, the outcome depends on where the band lands and whether it leaves room for upside. Read the RHP once the price band is out before making a decision.
Latest Manipal Health IPO news and updates
- SEBI approved the Manipal Health IPO on July 3, 2026
- IPO opens July 27 and closes July 29, 2026
- Fresh issue: ₹8,000 crore; OFS up to 4.32 crore shares
- Price band and lot size not declared yet
- Allotment July 30, listing August 1 on BSE and NSE
- Allotment status trackable at ipostatus.kfintech.com
Conclusion
Manipal Health Enterprises is a large hospital chain going public with a straightforward agenda: pay down debt and list at scale. The fresh issue structure makes sense. The network is real. Margins are improving. Whether the price band makes this attractive or fully priced is the one question that can't be answered until the RHP drops. Watch for it.
